Today: 9 June 2026
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus
9 June 2026
2 mins read

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

NEW YORK, June 9, 2026, 08:06 (EDT)

Snap Inc. shares are set to start Tuesday’s session lower after dropping for a second day, bucking gains in tech. The Snapchat owner ended Monday off 1.9% at $5.65. That came as the Nasdaq Composite added 0.9%. Snap now trades about 46% below its 52-week high of $10.41.

U.S. cash equities markets were set for a regular open. NYSE core trading hours go from 9:30 a.m. to 4 p.m. ET. Nasdaq’s 2026 schedule puts the next holiday closure on Juneteenth, June 19, not this Tuesday.

Futures looked solid ahead of the open, with Dow up 0.27%, S&P 500 futures rising 0.47% and Nasdaq 100 futures up 0.76%, according to Reuters. Chip stocks kept bouncing. That’s a stronger setup than Snap’s own action. “Investors are becoming more sensitive to inflation, interest rates and geopolitical risks,” Daniela Hathorn, senior market analyst at Capital.com, told Reuters. Reuters

That’s what puts the move in focus. Snap hasn’t lined up with the recent growth-stock recovery, while investors keep watching for proof that its cost cuts, push into subscription revenue, and AI products can help make up for a weaker ad market.

Snap last traded at $5.65 ahead of the New York open, according to the latest market quote. The stock is still showing a negative price-to-earnings ratio, as the company isn’t posting a net profit to compare with its share price.

Snap posted a 12% jump in first-quarter revenue to $1.529 billion, with net loss shrinking to $89 million. Adjusted EBITDA came in at $233 million, more than double last year’s. CEO Evan Spiegel said the company “returned to growth in daily active users,” meaning those logging in at least once a day. Snap Inc. Investor Relations

Ad revenue was slower. Reuters said last month Snap’s first-quarter ad sales were up 3% at $1.24 billion. North American daily active users fell. Snap warned of a $20 million to $25 million drop in March revenue linked to the Middle East conflict. Reuters also reported Snap called off a $400 million agreement with Perplexity AI.

Competition is real for Snap. Reuters reported the company faces pressure from bigger rivals like Meta’s Instagram and TikTok, which usually offer advertisers wider reach. Meta, Pinterest and Reddit also posted stronger first-quarter revenue numbers, according to the report.

Costs are still in focus. Snap in April said it planned to cut around 1,000 jobs, or 16% of full-time staff, according to Reuters. The company said it would also close over 300 roles that were open and aim for at least $500 million in annualized expense savings by the back half of 2026.

The risk is still there. If advertisers keep moving their budgets to bigger competitors, or if Snap’s push into augmented reality keeps burning cash without a quicker payback, layoffs might just delay the squeeze. Russ Mould, investment director at AJ Bell, told Reuters it was “still unclear” whether the cuts leave Snap with “a defensible business model.” Reuters

Snap’s next set date is June 16. CEO Evan Spiegel is expected to give a keynote at Augmented World Expo in Long Beach called “Making Computing More Human.” The company is betting on augmented reality—putting digital graphics or data on a user’s real-world view—and has linked its long-term story to its Specs eyewear project. newsroom.snap.com

Stock Market Today

  • AmpliTech Shares Surge 26.7% on 5G Open RAN Testing Update
    June 9, 2026, 9:16 AM EDT. AmpliTech (AMPG) shares surged 26.7% to $6.57 following its Open RAN testing update at the O-RAN Alliance Global PlugFest Spring 2026. The company's 64T64R Massive MIMO radio, which uses multiple antennas to enhance wireless capacity, was the only one of its kind tested with equipment from major operators including AT&T and Deutsche Telekom. Despite the strong test results, no new sales orders were announced, leaving investors cautious about future revenue impact. AmpliTech reported a 48.6% increase in first-quarter revenue to $5.35 million but remains unprofitable, narrowing its net loss to $1.52 million. The firm holds $18.4 million in cash and securities. Open RAN aims to enable multi-vendor interoperability in 5G networks, a critical push in telecom infrastructure modernization.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus
Previous Story

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock
Next Story

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Go toTop